Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul-Sep;14(3):173-178.
doi: 10.4103/atm.ATM_344_18.

Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region

Arafat Hussein Tfayli  1 , Ghina Bassam Fakhri  1 , Majd Sassine Al Assaad  1
Affiliations
Review

Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region

Arafat Hussein Tfayli et al. Ann Thorac Med. 2019 Jul-Sep.

Abstract

Lung cancer remains a major cause of cancer mortality with a 5-year survival in advanced stages around 4%. Platinum-based chemotherapy was routinely used as the standard of care in patients with advanced nonsmall cell lung cancer, but it is being progressively replaced by targeted molecular therapy. One of the molecular aberrations harbored by lung adenocarcinoma is the epidermal growth factor receptor (EGFR). A large ethnic variation has been reported in the prevalence of EGFR mutations in patients with lung adenocarcinoma. Data regarding its prevalence from the Middle East area remains limited. This paper aims at reviewing the data available for the prevalence of this mutation in the Middle Eastern patient population and comparing it with other reported series.

Keywords: Epidermal growth factor receptor; lung adenocarcinoma; middle east; prevalence.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Epidermal growth factor receptor mutation frequencies from major regions worldwide
See this image and copyright information in PMC

References

    1. World Health Organization Cancer Fact Sheet. 2016. [Last accessed on 2018 Nov 10]. http://www. who.int/mediacentre/factsheets/fs297/en/ Last Updated on 2018 Sep 12.
    1. Malik PS, Jain D, Kumar L. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncology. 2016;91(Suppl 1):26–34. - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. - PubMed
    1. Fakhruddin N, Mahfouz R, Farhat F, Tfayli A, Abdelkhalik R, Jabbour M, et al. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: A retrospective study of the Lebanese population. Oncol Rep. 2014;32:2223–9. - PubMed